News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
White House To Loosen Controls On Heroin Addiction Treatment
Taylor Cox , Benzinga Staff Writer-July 06, 2016 9:00am
Click For Article
The Wall Street Journal recently reported President Obama’s administration will loosen its strict controls on a medication called buprenorphine, which is used to treat addiction to heroin and other opioid-based drugs.
The Department of Health and Human Services up until now only allowed doctors to prescribe the medication to 100 patients at a time. Under the new rules, up to 275 patients at a time can be prescribed the drug. The limits were designed to restrict access to the substance, which addicts sometimes trade on the black market to opioid abusers seeking to avoid painful withdrawal symptoms. An unintended consequence to the tight controls became the inability/difficulties of finding a legal way to obtain the medicine from a doctor.
Related Link: Heat Wave: Here's How The S&P Has Performed Every July Since The Financial Crisis
This could spell good news for companies like Titan Pharmaceuticals, Inc.
TTNP 0.85%
and BioDelivery Sciences International, Inc.
BDSI 4.26%
, two companies that have been working on an injectable form of buprenorphine.
Titan recently received approval from the FDA for the first injectable implant in the United States, which will deliver a dosage of the medicine to patients, especially those who find methadone to be too addicting.
Shares of both Titan and BioDelivery over the last month have spiked but fallen to remain pretty much flat; however, this news may be a catalyst for these two pharmaceuticals.
Blessings to All
TRUTH
In BDSI @ $1.95. So far this level has held over the past few days and plenty of upside:
Not necessarily long, but with opioid concerns a area to invest in.
BDSI
$BDSI $7 & Climbing...could see $7.40+ today imo
|
Followers
|
46
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
408
|
|
Created
|
06/14/09
|
Type
|
Free
|
| Moderators | |||
http://www.bdsinternational.com/
http://finance.yahoo.com/q/ks?s=BDSI
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The company’s products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina.
